Open AccessActivity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods
Author(s) -
Shazad Mushtaq,
Marina Warner,
Alan P. Johnson,
David M. Livermore
Publication year - 2004
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkh401
Subject(s) - dalbavancin , microbiology and biotechnology , agar dilution , agar , staphylococcus aureus , agar dilution method , staphylococcus , medicine , antibiotics , biology , minimum inhibitory concentration , bacteria , vancomycin , genetics
Dalbavancin is a long-half-life (9-12 days) glycopeptide, now in Phase 3 development. Its pharmacokinetics may facilitate home intravenous therapy, early discharge and long prophylaxis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom